
Fulgent Genetics FLGT
$ 26.92
-0.81%
Quarterly report 2025-Q3
added 11-07-2025
Fulgent Genetics EV/EBITDA Ratio 2011-2025 | FLGT
Annual EV/EBITDA Ratio Fulgent Genetics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.58 | 8.07 | 143 | -21.5 | -44.8 | 104 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 143 | -44.8 | 31.9 |
EV/EBITDA Ratio of other stocks in the Diagnostics research industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
0.387 | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
28.1 | - | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
-43.6 | $ 16.71 | -0.83 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
-1.51 | $ 16.22 | 2.97 % | $ 175 M | ||
|
Accelerate Diagnostics
AXDX
|
-5.56 | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
-26.9 | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
-7.71 | $ 1.57 | -3.4 % | $ 2 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-73.4 | - | - | $ 562 M | ||
|
Castle Biosciences
CSTL
|
-21.2 | $ 38.53 | -0.26 % | $ 1.07 B | ||
|
DarioHealth Corp.
DRIO
|
-1.05 | $ 11.99 | 0.84 % | $ 340 M | ||
|
Chembio Diagnostics
CEMI
|
-1.23 | - | 0.22 % | $ 16.8 M | ||
|
DexCom
DXCM
|
39.5 | $ 66.15 | -1.22 % | $ 25.5 B | ||
|
Danaher Corporation
DHR
|
20.1 | $ 226.11 | -0.17 % | $ 165 B | ||
|
Exact Sciences Corporation
EXAS
|
-20.8 | $ 101.52 | 0.01 % | $ 18.8 B | ||
|
Global Cord Blood Corporation
CO
|
-3.52 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-13.6 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-2.67 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-2.67 | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
-2.44 | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
20.8 | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
-100 | $ 19.95 | -2.97 % | $ 1.07 B | ||
|
Celcuity
CELC
|
-2.38 | $ 101.73 | -3.34 % | $ 4.01 B | ||
|
Enzo Biochem
ENZ
|
58.3 | - | -8.98 % | $ 14.8 K | ||
|
Anixa Biosciences
ANIX
|
-2.25 | $ 3.29 | -8.24 % | $ 105 K | ||
|
Co-Diagnostics
CODX
|
3.62 | $ 0.31 | -9.7 % | $ 9.1 M | ||
|
IQVIA Holdings
IQV
|
24.1 | $ 221.67 | -0.25 % | $ 40.2 B | ||
|
Guardant Health
GH
|
-28.8 | $ 103.94 | 1.83 % | $ 12.8 B | ||
|
Aspira Women's Health
AWH
|
-2.63 | - | -6.19 % | $ 10.5 M | ||
|
Heska Corporation
HSKA
|
141 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-1.42 | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
70.5 | $ 133.75 | -0.83 % | $ 21.3 B | ||
|
Charles River Laboratories International
CRL
|
22 | $ 196.94 | 2.05 % | $ 10.1 B | ||
|
Quotient Limited
QTNT
|
-5.32 | - | -11.32 % | $ 1.1 M | ||
|
Quest Diagnostics Incorporated
DGX
|
5.51 | $ 183.42 | 0.5 % | $ 20.4 B | ||
|
Biodesix
BDSX
|
-4.25 | $ 7.63 | -2.8 % | $ 989 M | ||
|
Mettler-Toledo International
MTD
|
827 | $ 1 405.95 | 0.86 % | $ 29.8 B | ||
|
Myriad Genetics
MYGN
|
-17.2 | $ 6.96 | -3.47 % | $ 631 M | ||
|
Laboratory Corporation of America Holdings
LH
|
8.7 | $ 261.21 | -1.12 % | $ 21.9 B | ||
|
ICON Public Limited Company
ICLR
|
38 | $ 181.89 | -2.51 % | $ 15 B | ||
|
NeoGenomics
NEO
|
-33.5 | $ 11.99 | 1.14 % | $ 1.52 B | ||
|
Neogen Corporation
NEOG
|
40.3 | $ 6.78 | -1.16 % | $ 1.47 B | ||
|
IDEXX Laboratories
IDXX
|
45.3 | $ 698.37 | -0.83 % | $ 57.6 B | ||
|
Lantheus Holdings
LNTH
|
-187 | $ 67.15 | 0.79 % | $ 4.65 B | ||
|
Agilent Technologies
A
|
27.4 | $ 139.73 | 0.05 % | $ 42.5 B | ||
|
Biomerica
BMRA
|
-6.24 | $ 2.43 | -4.8 % | $ 5.58 M | ||
|
Bioventus
BVS
|
26.4 | $ 7.53 | -0.26 % | $ 472 M | ||
|
Check-Cap Ltd.
CHEK
|
-0.674 | - | - | $ 9.42 M | ||
|
Motus GI Holdings
MOTS
|
0.351 | - | -34.28 % | $ 263 K | ||
|
Pacific Biosciences of California
PACB
|
-23.8 | $ 2.1 | -1.18 % | $ 533 M |